QualityStocks News - Amarantus BioSciences and Rainbow Biosciences Select NuPro as Product Candidate for Proposed Joint Venture

Share Article

Companies work to establish a joint-venture agreement centered on Amarantus’ NuPro diagnostic test

This transaction will allow Amarantus to gain significant upside in revenues...

QualityStocks would like to highlight Amarantus BioSciences, Inc., a publicly traded U.S. development-stage biotechnology company, focused on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson’s disease, traumatic brain injury (TBI), and other human diseases. The company owns the intellectual property rights to a therapeutic protein, known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), which corrects protein misfolding.

In the company’s news yesterday,

Amarantus BioSciences and Rainbow Coral Corp. subsidiary Rainbow Biosciences have selected Amarantus’ NuroPro as their target product candidate. The pending joint-venture agreement will establish a partnership to commercialize NuroPro, which is in development for the diagnosis of Parkinson’s disease.

The companies say the deal will enable completion of the final stages of the NuroPro program, which they anticipate will result in a commercially viable product.

NuroPro has already undergone a phase 1 human clinical trial, and the companies expect to initiate a phase 2 clinical study in 2013. Upon completion of the phase 2 trial, the joint venture will introduce NuroPro into the marketplace as a Laboratory Developed Test (LDT) in a Clinical Laboratory Improvement Amendment (CLIA) certified laboratory prior to engaging in the regulatory process with the U.S. Food and Drug Administration.

“Our focus on Parkinson’s disease has allowed us to gain considerable traction with partners who understand the potential value of the technologies we have in-house,” Gerald E. Commissiong, president & CEO of Amarantus stated in the press release. “This transaction will allow Amarantus to gain significant upside in revenues derived from the NuroPro asset while defraying the costs of the project in order to focus our internal resources on the MANF Program for Parkinson’s disease. As NuroPro advances toward commercialization, it could become a key competitive advantage for our MANF clinical development program.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website